Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
Carmel Pezaro(Royal Marsden NHS Foundation Trust), Gerhardt Attard(London Cancer), Aurelius Omlin(University of Zurich), Deborah Mukherji(American University of Beirut Medical Center), Nina Tunariu(Leicester Royal Infirmary), David Olmos(Spanish National Cancer Research Centre), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Alison Reid(Royal Marsden NHS Foundation Trust), George Seed(Institute of Cancer Research)
Cited by 44
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k